Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monother apies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma.
Lomustine and Bevacizumab in Progressive Glioblastoma
N o standard of care has been established for patients with progressive glio blastoma. Previous studies suggested that bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor, is safe and produces responses 1 that result in a decreased use of glucocorticoids and increased progressionfree survival. The BRAIN trial, 1 supported by a single group study, 2 led to accelerated approval in the United States, followed by a multitude of uncon trolled series and molecular 3 and imaging 4,5 bio marker research. Controlled data are lacking ex cept for those of the BELOB trial, 6 which support the use of bevacizumab in combination with lomustine; data from an Italian phase 2 study showed the efficacy of bevacizumab to be infe rior to that of fotemustine when used singly. 7 Randomized trials involving patients with newly diagnosed glioblastoma showed no overall sur vival benefit from bevacizumab alone. 810 In the BELOB trial, the rate of overall survival at 9 and 12 months was higher with the combi nation of bevacizumab and lomustine than with either agent alone. Because bevacizumab was not accessible in the Netherlands, crossover to bevacizumab in the control group was restricted (one patient). 6 The EORTC (European Organiza tion for Research and Treatment of Cancer) 26101 phase 2 trial was a fourgroup trial to evaluate the most effective sequence of bevacizu mab and lomustine treatment. It was nearing completion when the first internal report of the BELOB trial was released. No end point of the phase 2 EORTC 26101 trial had been evaluated before the expansion to a phase 3 trial. 11 After the ongoing phase 2 trial was modified into a phase 3 trial, patients were enrolled in a group receiving either bevacizumab and lomus tine in combination or lomustine as a single agent. Here, we report the final data on safety and efficacy in the phase 3 trial.
Me thods

Trial Design
This randomized phase 3 trial compared patients with glioblastoma who received lomustine alone (monotherapy group) with those who received a combination of lomustine and bevacizumab (com bination group) at first progression of glioblas toma after standard chemoradiotherapy. 12 The EORTC used four stratification criteria to cen trally randomly assign patients who had entered the trial 13, 14 (see the Methods section in the Sup plementary Appendix, available with the full text of this article at NEJM.org). The primary end point was overall survival, defined as the time from randomization to death. Secondary end points included progressionfree survival, land mark analyses for progressionfree and overall survival, toxic effects according to version 4.0 of the Common Terminology Criteria for Adverse Events, response rates according to the Response Assessment in NeuroOncology (RANO) criteria 15 (see the Methods section in the Supplementary Appendix), neurologic deterioration-free survival (defined as the time from randomization to docu mentation of neurologic deterioration or death), clinical or neurologic deterioration-free survival, glucocorticoid use, healthrelated quality of life of both patients and health care proxies, the de velopment of symptoms of neurocognitive dete rioration, and assessments of predictive factors.
Eligibility
Patients were accepted into the trial after histo logic confirmation of glioblastoma with unequiv ocal first progression after chemoradiotherapy at least 3 months after the end of radiotherapy. Tumor tissue was required for central review and translational research. Patients were excluded if they had undergone antiangiogenic treatment. Radiotherapy at a dose of no more than 65 Gy with stereotactic radiosurgery or brachytherapy was allowed if recurrence was histologically proven. Only non-enzymeinducing antiepileptic drugs were allowed (for further eligibility criteria, see the Methods section in the Supplementary Appendix).
Treatment
Patients in the monotherapy group received lo mustine at a dose of 110 mg per square meter of bodysurface area every 6 weeks (maximum dose, 200 mg). Patients in the combination group re ceived lomustine at a dose of 90 mg per square meter every 6 weeks (maximum dose, 160 mg) plus bevacizumab at a dose of 10 mg per kilo gram of body weight every 2 weeks. In both groups, the trial regimen was followed by the investigator's choice of treatment at further pro gression. In the combination group, if there were no hematologic toxic effects of a grade of more than 1 during the first cycle, the dose of lomustine was increased to 110 mg per square meter (maximum dose, 200 mg) for the second T h e ne w e ngl a nd jou r na l o f m e dicine cycle. In each cycle, which was defined as 6 weeks for each group, day 1 was the first day of medi cation.
Baseline Examinations and Follow-up
The baseline evaluation included magnetic reso nance imaging (MRI), questionnaires on health related quality of life, neurocognitive testing, full clinical and neurologic evaluations, electrocardi ography, complete blood count, blood chemical analyses, and urinalysis. All patients were evalu ated for vital signs, adverse events, blood counts, and urine dipstick results every 2 weeks. Between weeks 6 and 24, weekly full clinical and neuro logic workup, blood examinations, and MRI were performed; questionnaires on healthrelated quality of life and neurocognitive testing were performed every 3 months. After week 24, exami nations were carried out at 3month intervals.
Images were assessed according to RANO cri teria, 15 with additional quantification of changes on fluidattenuated inversion recovery (FLAIR) images or T 2 weighted images. 16 All the assess ments and interpretations of disease status were performed locally but with continuous central quality control and independent central assess ment (see the Methods section in the Supplemen tary Appendix).
Pathological Review and Molecular Testing
Pathological reviews and molecular testing were performed centrally with the use of archival tis sue from the primary surgery. Isocitrate dehy drogenase (IDH) mutations were assessed on the basis of the glioma CpG island methylator phe notype, 17 and O 6 methylguanine-DNA methyl transferase (MGMT) promoter methylation was assessed with the use of Illumina 450k methyla tion arrays based on the MGMTSTP27 model 18 (see the Methods section in the Supplementary Appendix).
Questionnaires on Health-Related Quality of Life
The EORTC Quality of Life Questionnaire-Core 30 (QLQC30) and EORTC braincancer module (BN20) are wellestablished tools that have been validated and translated into all eight languages of patients involved in this trial. 19 Items from both measurements were scaled, scored 20 (where by responses were aggregated and transformed to a linear scale that ranged from 0 to 100, in which a higher score represented a higher level of functioning [function scales] or a higher level of symptoms [symptom scales]), and evaluated. 21 If at least half the items in the scale were com pleted, the scale score was calculated with only those items for which values existed. Preselected scales for analysis were global health status, physical functioning, social functioning, motor dysfunction, and communication deficit. Scores for healthrelated quality of life during the last assessment after baseline until week 36 were calculated and compared between treatment groups, as well as mean changes from baseline until weeks 12, 24, and 36. A difference of at least 10 points between treatment groups was considered to be clinically relevant. More details are provided in the Methods section in the Sup plementary Appendix.
Assessment of Neurocognitive Functioning
Neurocognitive functioning was assessed with standardized psychometric instruments: the Hop kins Verbal Learning Test-Revised, 22 Trail Making Test (A and B), 23 and Controlled Oral Word As sociation. 24 Neurocognitive assessments were per formed in a fixed order with the use of alterna tive forms to control for test-retest effects at baseline and every 12 weeks (see the Methods section in the Supplementary Appendix).
Trial Oversight
Staff at the EORTC and the first author reviewed all the data. The EORTC was the trial sponsor and vouches for the integrity, accuracy, and com pleteness of the data. All the analyses were done by the investigators and EORTC staff, who vouch for the adherence of the trial to the protocol (available at NEJM.org). The first draft of the manuscript was written by the first author. No one who is not an author contributed to the writ ing of the manuscript. F. Hoffmann-La Roche supported EORTC 26101 through an educational grant and provided bevacizumab free of charge but had no role in analyzing the data or writing the manuscript.
Statistical Analysis
We calculated that at least 327 overall survival events (deaths) would be required for the trial to have 80% power to detect a hazard ratio of 0.72 (rate of overall survival at 9 months of 51.7% in the combination group and 40% in the mono therapy group), on the basis of a onesided log rank test at a significance level of 2.5%. The accrual assumptions for the two groups in the phase 3 trial are summarized in the Methods section in the Supplementary Appendix. Overall and progressionfree survival curves were estimat ed with the use of the Kaplan-Meier technique. Analyses were conducted on an intentiontotreat basis. Differences in overall and progressionfree survival between the two groups were formally compared with the use of a stratified onesided logrank test at a 2.5% significance level. The stratification factors are those used at random ization (except institution) and a variable indi cating whether the patient was recruited in the phase 2 or 3 portion. Analyses used the stratifi cation according to the EORTC online random ization system. The treatment effect was esti mated as a hazard ratio (with a twosided 95% confidence interval) with the use of a stratified Cox proportionalhazards model (same stratifi cation factors). Assessments of predictive factors are detailed in the Methods section in the Sup plementary Appendix.
R esult s
Patients
A total of 437 patients underwent randomiza tion; 149 (38 in the phase 2 part and 111 in the phase 3 part of the trial) received lomustine alone and 288 (77 and 211, respectively) received lomustine plus bevacizumab over a period of 37 months from November 2011 through December 2014 at 38 institutions in eight countries. Patient characteristics were well balanced between the two groups ( Table 1, and Table S1 in the Supple mentary Appendix). Molecular information was available for 367 of 437 patients (84.0%), and a central neuroradiologic review was performed in 418 of 437 patients (95.7%) (Fig. 1) .
Treatment Delivery and Adverse Events
Randomized treatment was started for 98.7% of the patients in the monotherapy group and 98.3% in the combination group (Fig. 1) . Patients in the monotherapy group received a median of 1 cycle of lomustine (range, 1 to 8), and patients in the combination group received a median of 3 cycles of lomustine (range, 1 to 8) and 3 cycles of bevacizumab (range, 1 to 16). The main reason for discontinuing treatment was disease progres sion, in 120 of 144 patients (83.3%) in the lomus tine group, 186 of 264 patients (70.5%) for lo mustine in the combination group, and 208 of 264 patients (78.8%) for bevacizumab in the combination group. The discrepancy between stopping bevacizumab and stopping lomustine in the combination group was a result of treat ment scheduling or toxic effects (15 Grade 3 to 5 adverse events occurred in 38.1% of the patients in the monotherapy group and in 63.6% of the patients in the combination group. Adverse events of grade 3 to 5 of special interest were pulmonary embolism, arterial hypertension, and hematologic toxic effects. One patient in the monotherapy group died from a lung infection that was unrelated to the tumor. In the combi nation group, five deaths were noted (two from myocardial infarction and one each from large intestine perforation, sepsis, and intracranial hemorrhage) ( Table 2) .
Efficacy End Points
With 329 overall survival events (75.3%), the combination treatment did not provide a sur vival advantage. The median overall survival was 8.6 months (95% confidence interval [CI], 7.6 to 10.4) in the monotherapy group and 9.1 months (95% CI, 8.1 to 10.1) in the combination group according to local assessments (hazard ratio for death in the combination group, 0.95; 95% CI, 0.74 to 1.21; P = 0.65) (Fig. 2A) . The median progressionfree survival was 1.5 months (95% CI, 1.5 to 2.5) in the monotherapy group and 4.2 months (95% CI, 3.7 to 4.3) in the combina tion group according to local assessments (hazard ratio for disease progression or death in the combination group, 0.49; 95% CI, 0.39 to 0.61; P<0.001) (Fig. 2B) . Landmark survival at 9 and 12 months is shown in Figure 2A .
No subgroup showed particular benefits from bevacizumab; male patients derived the least benefit. No factor predicted benefit (Table S2A in the Supplementary Appendix). A total of 397 of 430 patients (92.3%) had measurable disease, Percentages may not total 100 because of rounding. † The World Health Organization (WHO) performance status is scored on a scale of 0 to 5, with 0 indicating full activity, 1 unable to carry out heavy physical work, and 2 up and about more than half the day but unable to work. ‡ Data were gathered with the use of the European Organization for Research and Treatment of Cancer online randomization system. § These patients received a stable or decreasing dose for 7 days before magnetic resonance imaging at baseline. After disease progression occurred while they were receiving the trial treatment, 65.9% of the patients in the monotherapy group and 53.0% of the patients in the combination group received further therapy (401 patients had a progression event, of whom 368 had followup information), including crossovers to offlabel use of bevacizu mab in 35.5% of the monotherapy group and 18.7% of the combination group (Table 3) .
Health-Related Quality of Life
Data on healthrelated quality of life at baseline were available for 92.0% of the patients (402 of 437), with a decrease to 66.3% at week 36, limit ing further analysis. There were no significant differences between the treatment groups until week 36, when adherence favored the combina tion group (71.2%, vs. 50.0% in the monother apy group). No significant betweengroup dif ferences were observed for preselected scales, apart from a lower score for social functioning in the combination group than in the mono therapy group (mean, 66 vs. 81; P = 0.001) ( Table  S4 in the Supplementary Appendix); the differ ence was considered to be clinically relevant. The baseline score for social functioning was 66 in the monotherapy group and 71 in the combina Death* 1 (0.7) 5 (1.8) * In the monotherapy group, one patient died from a lung infection. In the combination group, two patients died from myocardial infarction and one each died from large-intestine perforation, sepsis, and intracranial hemorrhage. T h e ne w e ngl a nd jou r na l o f m e dicine tion group, with patients in the combination group showing stable social functioning and patients in the monotherapy group showing im proved social functioning. There were no signifi cant differences between the groups in the mean change in healthrelated quality of life from baseline at weeks 12 and 24, but at week 36, scores for global health status and social func tioning were lower in the combination group than in the monotherapy group (mean change, −5.6 vs. 4.6 for global health status and −1.1 vs. 9.3 for social functioning, with available data from 35 patients in the combination group and 9 patients in the monotherapy group). 
mo
If progression was not included as an event, there was no significant difference in time to deterioration in healthrelated quality of life be tween the monotherapy group and the combina tion group (median, 13.0 weeks and 13.1 weeks, respectively; P = 0.65). This contrasts with deteri orationfree survival, which was longer in the combination group than in the monotherapy group (12.4 weeks vs. 6.7 weeks; P<0.001), re flecting the difference in time to progression.
Neurocognitive Outcome
Adherence to the assessment of neurocognitive function was 94.5% at baseline and 61.4% at the third followup visit at 36 weeks. Adherence never differed significantly between the treatment groups. The primary analysis compared the six neurocognitive function scores at the last dis ease assessment before or at the third followup visit. Time points of the assessment of neuro cognitive function are shown in Table S5 in the Supplementary Appendix. No significant differ ences were observed at baseline and followup between the two trial groups (Fig. S1 in the Supplementary Appendix).
MGMT Status
Technically sound MGMT results could not be obtained for 97 patients; in 70, no tumor tissue of appropriate quality was available. Of the re maining 270 patients, 124 (45.9%) had MGMT promoter hypermethylation. In the population as a whole, MGMT promoter methylation was prog nostic, with a median progressionfree survival of 2.8 months (95% CI, 2.6 to 2.9) among pa tients with unmethylated promoters (146 patients with 143 events), 5.7 months (95% CI, 4.4 to 6.9) among patients with methylated promoters (124 patients with 103 events), 3.0 months (95% CI, 2.8 to 4.2) among patients with undetermined results (97 patients with 89 events), and 2.9 months (95% CI, 2.7 to 3.5) among patients for whom no material was available (70 patients with 68 events) ( Table S6 in the Supplementary Appendix). The hazard ratio for disease progres sion or death with methylated MGMT status as compared with unmethylated MGMT status was 0.37 (95% CI, 0.29 to 0.49). MGMT status was not predictive of efficacy outcomes with the combi nation treatment (Table S2B and S2C in the Sup plementary Appendix). When data were separated according to treatment and MGMT status, pro gressionfree but not overall survival was longer in the combination group than in the mono therapy group, whether the MGMT promoter was unmethylated or methylated in tumors (Table S7 in the Supplementary Appendix). Patients with methylated MGMT status had a longer median overall survival from the time of randomization than those with unmethylated MGMT status: 13.5 months (95% CI, 10.6 to 15.4) versus 8.0 months (95% CI, 5.9 to 8.8) (hazard ratio for death, 0.48; 95% CI, 0.35 to 0.66; P<0.001).
Discussion
EORTC 26101 provided phase 3 data on the effi cacy of bevacizumab in patients with progressive glioblastoma. Adding bevacizumab to lomustine did not confer a survival advantage over lomus tine alone but prolonged progressionfree survival somewhat. This benefit was consistent across the assessments of the trial, although there were some local and central deviations. EORTC 26101 shows the feasibility of implementing a uniform MRI protocol in an international neurooncology trial. The central review deemed progression earlier than the local assessment in 96 patients in the combination group (Table S3 in the Sup  plementary Appendix) . 25 There were no unexpected findings from as sessments of toxic effects, although absolute numbers were higher and deaths more frequent in the combination group than in the mono therapy group. Although important given the lack of overall survival benefit, the higher num bers of adverse effects should be assessed relative to the longer treatment period in the combination group (Table 2 ). In addition to the difference in toxic effects, combination therapy had a negative effect on scores of social functioning and global health status at late time points (Table S4 in the Supplementary Appendix). These results are con sistent with findings regarding healthrelated quality of life in the BELOB trial. 26 The addition of bevacizumab did not improve neurocognitive functioning, although the high performance level at baseline may prevent a systematic improve ment. However, the combination of bevacizu mab and lomustine also did not lead to poorer neurocognitive function than lomustine alone, although the 36 weeks during which patient ad herence was satisfactory might have been too short to observe longterm differences between the groups (Fig. S1 in the Supplementary Ap pendix).
Although earlier reports from the BRAIN trial (involving patients with recurrent glioblastoma) 1 and from the Avastin in Glioblastoma trial (in volving patients with newly diagnosed glioblas toma) 8 suggested that bevacizumab had glucocor ticoidsparing effects, the addition of bevacizumab in the current trial did not result in reduced use of glucocorticoids. MGMT status was not predic tive of benefit from the combined therapy. 27 Earlier data suggested that lomustine had little effect on MGMT unmethylated glioblastomas, and adding bevacizumab did not alter this con clusion. 6 EORTC was unable to confirm the conclusion of phase 2 trials that the addition of bevacizu mab to lomustine improves survival in patients with progressive glioblastoma. The effect on progressionfree survival was not associated with an increase in overall survival, and combination therapy was associated with increased toxicity.
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